510
structural features. In the case of PMA (1), these include a carbonyl group at C-3, hydroxyl groups at
C-4, C-9, and C-20, and a long-chain hydrophobic portion at C-12, indicating that an acetoxy group at
C-13 is not important for the interaction of PMA (1) with PKC.
However, the biological evaluation of 13-deoxyphorbol esters3 and photoaffinity labeling by 13-
diazoacetyl phorbol ester derivative or 13-trifluorodiazopropionyl phorbol ester derivative4,5 have sug-
gested that the ester group at C-13 in phorbol esters is located in close proximity to PKC and interacts
with PKC in phorbol ester-PKC-phospholipid complexes. Moreover, some recent reports on molecular
modeling have supported the importance of the C-13 ester group.6 It is of interest to assume that the
C-13 acetoxy group would form a hydrogen bond with the C-9 hydroxyl group, not with PKC, based
on X-ray crystallography7 and MM calculation,6 suggesting that these functional groups would interact
with regulatory domain of PKC by hydrophobic interaction through a hydrogen bond between the C-
13 acetoxy group and the C-9 hydroxyl group. Therefore, 9,13-dideoxyphorbol 3 would be quite an
interesting compound, providing further information on structure–activity relationships of phorbols to
propose a more precise pharmacophore model. In this communication we report an efficient method for
the synthesis of versatile intermediates 7, 8, 19, 25 and 27 leading to 13-deoxy- and 9,13-dideoxyphorbols
2 and 3.
Scheme 1. Reagents and conditions: (a) Me2CuLi (2.0 equiv.), THF, 0°C, 30 min, 98% (b) TMSCl (3.0 equiv.), LHMDS (1.2
equiv.), THF, −78°C→rt, 2 h, 78% (c) 36% HCHO aq., Yb (OTf)3 (5.0 mol%) rt, 85 h, 81% (d) TBSCl (1.5 equiv.), imidazole
(3.0 equiv.), DMF, rt, 2 h, 83% (e) LDA (1.3 equiv.), zirconocene dichloride (1.3 equiv.), PhSeBr (1.1 equiv.), THF, −78°C, 2
h, 84% (f) mCPBA (1.5 equiv.), CH2Cl2, rt, 2 h, 85% (g) n-Bu4NF (1.2 equiv.), THF, 0°C, 2 h, quant. (h) (1) 30% H2O2 aq. (4.0
equiv.), NaOH (0.1 equiv.), THF, 0°C, 2 h, (2) pivaloyl chloride (1.5 equiv.), pyridine (3.0 equiv.), CH2Cl2, rt, 10 h, 81% (two
steps) (i) Al–Hg, THF:EtOH:H2O (3:2:1), −45°C, 4 days, 87% (j) TBDPSCl (2.0 equiv.), imidazole (4.0 equiv.) DMF, rt, 6 h,
60% (k) SmI2 (2.0 equiv.), THF, −78→0°C then PhSeBr (2.0 equiv.), 0°C→rt, 15 min, 75% (l) TMSCl (3.0 equiv.), LHMDS
(1.3 equiv.), THF, −78°C, 10 min, 97% (m) 36% HCHO aq., Yb(OTf)3 (10 mol%), THF, rt, 5 h, 64% (n) 30% H2O2 aq. (10
equiv.), THF, rt, 5 min, quant.
Our strategy for synthesis of 3 basically stands on that for the synthesis of 2.3 However, the synthesis
of the intermediate 7 was rather lengthy in our previous attempt (11 steps from (+)-3-carene, 30%
overall yield).3 Therefore, a shorter synthetic route to 7, which is also useful for the medicinal chemistry
of 13-deoxyphorbol esters 2, was first investigated. As a result, we succeeded in synthesizing 7 with
improved and shorter procedures than the previous one (seven steps from (+)-3-carene, 42% overall
yield) (Scheme 1). Highly regioselective enol silylation of 5, which is easily derived from (+)-3-carene
in five steps,8 with LHMDS and TMSCl, and subsequent aldol reaction of the enol silyl ether using 36%
9
aqueous HCHO and 5 mol% of Yb(OTf)3 gave 7 in 63% yield from 5. The stereochemistry of 7 thus
prepared was unequivocally determined by comparison with an authentic sample.3 It is noteworthy that